| __timestamp | Alnylam Pharmaceuticals, Inc. | Viridian Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 44526000 | 7751000 |
| Thursday, January 1, 2015 | 60610000 | 10251000 |
| Friday, January 1, 2016 | 89354000 | 9575000 |
| Sunday, January 1, 2017 | 199365000 | 10912000 |
| Monday, January 1, 2018 | 382359000 | 11049000 |
| Tuesday, January 1, 2019 | 479005000 | 11646000 |
| Wednesday, January 1, 2020 | 588420000 | 13265000 |
| Friday, January 1, 2021 | 620639000 | 25805000 |
| Saturday, January 1, 2022 | 770658000 | 35182000 |
| Sunday, January 1, 2023 | 795646000 | 94999000 |
| Monday, January 1, 2024 | 975526000 |
In pursuit of knowledge
In the competitive world of biotechnology, managing operational costs is crucial for success. Alnylam Pharmaceuticals, Inc. and Viridian Therapeutics, Inc. offer a fascinating study in contrasts over the past decade. From 2014 to 2023, Alnylam's Selling, General, and Administrative (SG&A) expenses surged by over 1,600%, reflecting its aggressive expansion and investment in innovation. In contrast, Viridian's SG&A costs grew by approximately 1,125%, indicating a more measured approach.
Alnylam's expenses peaked in 2023, reaching nearly 800 million, a testament to its commitment to growth. Meanwhile, Viridian's expenses, though significantly lower, showed a notable increase in 2023, suggesting strategic scaling. This divergence highlights the varied strategies biotech firms employ to navigate the industry's challenges. As these companies continue to evolve, their financial strategies will remain a key indicator of their future trajectories.
SG&A Efficiency Analysis: Comparing Eli Lilly and Company and Alnylam Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Merck & Co., Inc. and Alnylam Pharmaceuticals, Inc.
Takeda Pharmaceutical Company Limited vs Viridian Therapeutics, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Pharming Group N.V. Trends and Insights
SG&A Efficiency Analysis: Comparing Alnylam Pharmaceuticals, Inc. and Protagonist Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Alnylam Pharmaceuticals, Inc. and Mesoblast Limited
Alnylam Pharmaceuticals, Inc. and Geron Corporation: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Dynavax Technologies Corporation Trends and Insights
Operational Costs Compared: SG&A Analysis of Alnylam Pharmaceuticals, Inc. and Novavax, Inc.
SG&A Efficiency Analysis: Comparing Ultragenyx Pharmaceutical Inc. and Viridian Therapeutics, Inc.
Protagonist Therapeutics, Inc. or Viridian Therapeutics, Inc.: Who Manages SG&A Costs Better?
Ligand Pharmaceuticals Incorporated and Viridian Therapeutics, Inc.: SG&A Spending Patterns Compared